Collegium Pharmaceutical, Inc. COLL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $74.95M+70.7% | $62.87M-9.1% | $58.44M-34.0% | $36.27M-63.7% | $43.89M-53.0% | ||
| $3.55M-11.8% | $4.18M+8.5% | $4.3M+14.2% | $4.21M+15.3% | $4.03M+12.1% | ||
| $41.26M+13.2% | $41.91M+29.3% | $39.75M+25.0% | $37.26M+18.2% | $36.45M+27.6% | ||
| -$26.09M-13.7% | -$25.66M+4.3% | -$25.74M-51.5% | -$22.34M-138% | -$22.94M-252% | ||
| $4.79M-14.5% | $5.34M-11.2% | $5.49M-16.3% | $5.35M-28.3% | $5.6M-31.1% | ||
| $60K-99.4% | -$17.2M-481% | $5.42M+147% | -$15.32M— | $9.52M— | ||
| $5.62M+150% | $5.45M+139% | $116K+101% | -$6.87M— | -$11.21M— | ||
| —— | —— | —— | —— | $4.37M+44.3% | ||
| —— | —— | —— | —— | —— | ||
| -$6.44M-127% | $7.97M-43.4% | $1.73M-83.9% | $23.5M+176% | $24.17M+1,711% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $186.26M+30.4% | ||
| -$396K+89.3% | -$1.18M+59.4% | -$4.08M— | -$4.06M— | -$3.7M— | ||
| $331.04M+59.6% | $329.32M+53.9% | $290.92M+43.5% | $212.48M-23.2% | $207.44M-32.9% | ||
| $1.21M-35.6% | $1.74M+5.3% | $1.62M+30.1% | $1.68M+57.2% | $1.88M+121% | ||
| -$52.23M+81.3% | -$63.53M+77.9% | -$55.23M+81.7% | -$273.32M-388% | -$279.31M-215% | ||
| $626.66M+702% | $635.56M+490% | $64.58M-53.0% | $48.44M-73.6% | $78.13M-57.4% | ||
| $3.12M-58.9% | $4.28M-58.2% | $3.47M-74.0% | $2.18M-83.8% | $7.59M-15.6% | ||
| $17.69M+4.7% | $12.85M-33.0% | $12.26M-35.9% | $11.44M-40.3% | $16.89M+25.1% | ||
| —— | —— | —— | $7.56M— | $555K— | ||
| -$106.35M— | -$110.25M— | -$129.7M— | —— | —— | ||
| $172.46M— | $155.55M— | —— | —— | —— | ||
| $69.18M+3.8% | $68.76M+10.1% | $72.29M+15.1% | $68.43M+4.3% | $66.66M-6.4% | ||
| $57.63M+6.0% | $60.04M+15.3% | $48.38M-17.1% | $48.48M-3.2% | $54.37M+130% | ||
| $926K-52.2% | $1.07M-47.1% | $1.19M-46.2% | $1.48M-35.0% | $1.94M— | ||
| $4.79M-14.5% | $5.34M-11.2% | $5.49M-16.3% | $5.35M-28.3% | $5.6M-31.1% | ||
| —— | —— | —— | —— | $186.26M+30.4% | ||
| -$396K+89.3% | -$1.18M+59.4% | -$4.08M— | -$4.06M— | -$3.7M— | ||
| $3.55M-11.8% | $4.18M+8.5% | $4.3M+14.2% | $4.21M+15.3% | $4.03M+12.1% | ||
| $2.13M— | $2.85M— | —— | —— | —— | ||
| -$6.44M-127% | $7.97M-43.4% | $1.73M-83.9% | $23.5M+176% | $24.17M+1,711% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $416K+567% | -$110K+0.9% | -$102K+48.2% | ||
| —— | —— | —— | —— | —— | ||
| $626.66M+702% | $635.56M+490% | $64.58M-53.0% | $48.44M-73.6% | $78.13M-57.4% | ||
| $526K+279% | $319K+72.4% | $360.25K+37.6% | $216.5K— | $138.75K— | ||
| —— | $0-100% | $1.02M-66.7% | $2.05M0.0% | $3.07M+200% | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | $7.56M— | $555K— | ||
| —— | $0-100% | $24.75K-86.9% | $49.5K-82.2% | $74.25K-79.8% | ||
| $57.63M+6.0% | $60.04M+15.3% | $48.38M-17.1% | $48.48M-3.2% | $54.37M+130% | ||
| $329.83M+60.3% | $327.58M+54.1% | $289.3M+43.5% | $211.05M-23.4% | $205.8M-33.2% | ||
| $329.83M+60.3% | $327.58M+54.1% | $289.3M+43.5% | $211.05M-23.4% | $205.8M-33.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Collegium Pharmaceutical, Inc. generate?
- Collegium Pharmaceutical, Inc. (COLL) generated $331.0M in operating cash flow over the trailing twelve months.
- What is Collegium Pharmaceutical, Inc.'s free cash flow?
- After $1.2M of capital expenditures, Collegium Pharmaceutical, Inc.'s free cash flow was $329.8M over the trailing twelve months, up 60.3% year over year.
- Where does Collegium Pharmaceutical, Inc.'s cash flow data come from?
- Every line is extracted from Collegium Pharmaceutical, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
